Analysts forecast that Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) will announce earnings per share (EPS) of ($0.16) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Cyclacel Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.18). The business is expected to report its next quarterly earnings results on Monday, February 11th.

On average, analysts expect that Cyclacel Pharmaceuticals will report full-year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.67) to ($0.58). For the next financial year, analysts expect that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.82) to ($0.58). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its earnings results on Monday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01).

A number of equities research analysts have recently weighed in on CYCC shares. Roth Capital set a $8.00 target price on Cyclacel Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 4th. LADENBURG THALM/SH SH started coverage on Cyclacel Pharmaceuticals in a report on Friday, September 7th. They set a “buy” rating and a $6.25 target price for the company. HC Wainwright set a $7.00 target price on Cyclacel Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 10th. Zacks Investment Research raised Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Friday, November 16th. Finally, ValuEngine raised Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $5.63.

A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC increased its stake in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 76,500 shares during the period. Renaissance Technologies LLC owned approximately 0.76% of Cyclacel Pharmaceuticals worth $130,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.50% of the company’s stock.

Shares of CYCC traded up $0.01 during midday trading on Friday, reaching $0.91. 348,751 shares of the stock were exchanged, compared to its average volume of 59,894. Cyclacel Pharmaceuticals has a twelve month low of $0.85 and a twelve month high of $2.14.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Featured Article: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.